YB-101, a first-in-class anti-TSHR antibody, is advancing through clinical trials to address significant unmet needs in Graves' Disease and thyroid eye disease. Backed by $200M in funding and a strong leadership team, the company targets a $2B+ US market with a differentiated, convenient therapy.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.